IONETIX Promotes Ronald J. Lissak
to Newly Created Position, Vice President, Growth

IONETIX Promotes Ronald J. Lissak
to Newly Created Position, Vice President, Growth

Nuclear Medicine and Imaging Industry Veteran and Entrepreneur to Lead Marketing and Growth Initiatives

Lansing, MI – August 28, 2020 – IONETIX, the leading provider of Ammonia N-13 as a service to health systems, hospitals, cardiology and radiology practice groups in the United States, today announced that Ronald J. Lissak has been promoted to the newly created position, Vice President, Growth, where he will lead the company’s global marketing efforts

Mr. Lissak brings over twenty years of management, leadership, sales and marketing expertise as well as nuclear medicine and imaging industry experience to the new position.  Prior to taking on this new role, he served as Vice President Channel Sales and Marketing, North East at IONETIX.     

Before joining IONETIX, Mr. Lissak founded and ran a highly successful independent healthcare consultancy where he developed business plans, funding programs, marketing campaigns and corporate transition programs for clients in the pharmaceutical, drug manufacturing, nuclear medicine and radiology fields.    

Prior to that, Mr. Lissak was the Founder and CEO of the Integral Group of Companies, which specialized in developing and managing outsourced Positron Emission Tomography (PET/CT) and Nuclear Medicine facilities in partnership with pre-eminent academic medical centers, community hospitals and private radiology practices. Integral became one of the largest independent molecular imaging companies within 5 years, serving more than 18,000 patients/year at its peak. 

Prior to his tenure at Integral, Mr. Lissak served as the Chief Financial Officer at Unilease Computer Corporation. Prior to that, he was the founder of Lissak and Company, Certified Public Accountants.

Mr. Lissak has a deep commitment to education and research in fields of nuclear medicine and imaging. He participated in implementing quality assurance and reporting requirements for 21 research protocols at the Lombardi Cancer Center in Wisconsin, developed the protocols for the first outpatient center to utilize PET/CT in radiation therapy treatment planning, established and created the M. Donald Blaufox Laboratory for Metabolic Imaging at the Albert Einstein Medical College in New York, and developed first Speaker’s Bureau dedicated to PET education.

Mr. Lissak is a Member of the Board of the Foundation of Peripheral Neuropathy, and a past Member of the Board of Overseers and the Executive Committee and Chairman of the Communications Committee for The Albert Einstein College of Medicine, Bronx NY, a past Member of the Board and Treasurer of the Carlos Otis Clinic, Stratton VT, and the New York Academy of Medicine. He remains an active participant in the Society of Nuclear Medicine and Molecular Imaging.

Mr. Lissak earned his Bachelor of Science degree from Syracuse University, and attended the Harvard Business School for Owner/President Management Program for Entrepreneurial Management.

IONETIX is a pioneering radio-pharmaceutical company providing Ammonia N-13 as a service to cardiac PET imaging providers (in the US). A growing number of key opinion leaders consider Ammonia N-13 the optimal tracer for myocardial perfusion imaging. IONETIX  manufactures, installs, operates and manages cyclotrons and produces doses of Ammonia N-13, as ordered by physicians, at or near the imaging suite. The IONETIX cyclotron has a significantly smaller footprint than traditional machines and the unique Ammonia-as-a-service model makes using Ammonia N-13 easy and affordable for the cardiac imaging community.